Button 0Button 1Button 2Button 3Button 4Button 5


Noribogaine Stimulates Naloxone-Sensitive
[35S]GTPgammaS Binding

Pablo JP, Mash DC

Department of Neurology, University of Miami School of Medicine,
Florida 33136, USA.

ABSTRACT:

Noribogaine is formed in vivo by the O-demethylation of the indole alkaloid ibogaine. We report here that noribogaine acts as a full agonist at the mu-opioid receptor. Noribogaine-stimulated guanylyl 5'gamma-[35S]thio]triphosphate ([35S]GTPgammaS) was studied in rat thalamic membranes to measure activation of guanine nucleotide binding proteins (G-proteins) in the presence of excess GDP. Noribogaine caused a 170% increase above basal [35S]GTPgammaS binding at sub-micromolar effective concentrations (EC50) in a naloxone-sensitive manner, confirming that this effect was an opioid receptor-mediated process. The level of intrinsic activity for noribogaine in these assays was comparable to the full agonists DAMGO and morphine. In contrast, ibogaine had no significant effect on [35S]GTPgammaS binding over a similar concentration range. The efficacy of noribogaine as a full mu-opioid agonist may explain ibogaine's ability to block the acute signs of opiate withdrawal and its suppressive effects on morphine self-administration.

Previous Article


Copyright © 2005 Advanced Health Transitions, Inc. All Rights Reserved

Disclaimers: Advanced Health Transitions is not affiliated with any academic medical center or substance abuse treatment program in the United States or elsewhere. Ibogaine has not been approved for use in the United States, Canada or Europe. This is an experimental drug that is not FDA-approved.